Home / Going-concern warnings / REVIVA PHARMACEUTICALS HOLDINGS, INC.
Filed 2025-04-03 路 Form 10-K 路 Accession 0001437749-25-010791 nano
Price before filing: $11.23 (2025-04-02 close, split/dividend-adjusted)
Market cap at flag: $28.1M (2025-04-03) 路 Latest: $6.6M (2026-10-16)
| Window | RVPH | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +51.8% | -0.2% | +52.0% | 2025-05-05 |
| 90 days | -31.4% | +10.2% | -41.7% | 2025-07-02 |
| 180 days | -34.4% | +18.7% | -53.1% | 2025-09-30 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: independent auditor report in Form 10-K (period 2024-12-31)
Why this score: in auditor's report; also within 90 days: Auditor change
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.